glp-1 agonist weight loss medications alternatives Emerging Drugs and What Pharmacies Need to Know GLP-1 Drug Savings: A Complete

Survodutide Dosing# Survodutide Phase 2 tested doses of 0.6, 2.4, 3.6, and 4.8 mg once weekly over 46 weeks

The authors hope that it may serve as a basis for further discussion in order to expand the possibility of more options for individualized treatments to be applied in the future, which appropriately fit the specific characteristics and needs of each patient

Repurposing GLP-1 Receptor Agonists for Parkinsons Disease: Current Evidence and Future Opportunities

This head-to-head randomized trial directly compared tirzepatide with semaglutide for obesity treatment and provides high-level evidence for the magnitude of weight loss achievable with current incretin-based pharmacotherapy

PGC1a, peroxisome proliferator-activated receptor c coactivator 1a